newsfilter
← Latest News
GlobeNewswire·

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5